
Feb 28 (Reuters) - Merck & Co Inc MRK.N:
WELIREG® (BELZUTIFAN) PLUS LENVIMA® (LENVATINIB) REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 30% COMPARED TO CABOZANTINIB IN CERTAIN PREVIOUSLY TREATED PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
MERCK & CO INC - WELIREG PLUS LENVIMA REDUCES RISK OF DISEASE PROGRESSION BY 30%
MERCK & CO INC - WELIREG PLUS LENVIMA SHOWS SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL
MERCK & CO INC - FDA ACCEPTS REVIEW OF TWO SUPPLEMENTAL NDAS FOR WELIREG PLUS LENVIMA